Pepgen will stop development of its Duchenne MD exon-skipping therapy PGN-ED051 after increases in dystrophin levels proved ...

With FSHD, the need to adapt seems never-ending, which is why columnist Robin Stemple and others feel like they're constantly ...

CureDuchenne is investing $1 million in Entos Pharmaceuticals to support the development of a new DMD gene therapy.

After taking a day for reflection on her sons' lives with DMD, columnist Betty Vertin says she feels more on top of their care.